Risk factor
Meaningful price volatility
Profitability factor
Greatly undervalued vs peers
About
SD BioSensor Inc., a global leader in in-vitro diagnostics, delivers advanced point-of-care testing solutions from its base in South Korea. The company's diverse product portfolio features the STANDARD Q rapid diagnostic platform, offering quick results for various parameters including COVID-19. For laboratory settings, they provide the STANDARD F, a multi-parametric, random-access fluorescence immunoassay system, and the STANDARD E, an ELISA-based solution ideal for extensive screening programs. Their STANDARD M system brings molecular diagnostics closer to the patient, comprising analyzers, assay menus, qPCR reagents, and nucleic acid extraction kits. Furthermore, the procell Dx range focuses on diagnosing infectious diseases such as tuberculosis and SARS-CoV-2, alongside assessing immune status through interferon-gamma release assays. Blood glucose meters also form part of their offerings. Founded in 2010, SD BioSensor is headquartered in Suwon.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is neutral on EV/EBITDA, underpriced on P/FC.
Target Price
The average target price of 137310.KS is 9000 and suggests 40.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to